Christopher Espelin

Christopher Espelin has over 13 years of experience in the pharmaceutical and biotechnology industries. Christopher began their career in 2006 as a Postdoctoral Associate at Harvard Medical School, where they collaborated with the Department of Systems Biology, the MIT Department of Biological Engineering and the Pfizer Systems Biology Group to investigate the cell signaling pathways underlying Rheumatoid Arthritis. In 2007, Christopher joined Pfizer as a Senior Research Scientist, where they evaluated the effects of p38 inhibitors alone and in combination with other small molecule inhibitors on cell signaling pathways and regulation of cytokines/growth factors relevant for rheumatoid arthritis/inflammation. Christopher also led a group establishing and interrogating cell models of adipocytes, muscle, liver and pancreas for the identification of treatments for diabetes. In 2010, Christopher moved to Merrimack as a Principal/Senior Scientist. Christopher then joined ImmunoGen, Inc. in 2017 as a Translational Medicine Lead. Christopher is currently employed as the Senior Director of Pharmacology and Translational Sciences at Mediar Therapeutics.

Christopher Espelin received their PhD in Biology (Biochemistry) from the Massachusetts Institute of Technology. Prior to that, they obtained a Molecular Genetics degree from The Ohio State University. Christopher also holds a BS in Biology from Saint Louis University. Christopher's educational journey began at Bishop Guertin High School.